SCHEMBL3605920

SCHEMBL3605920

CCOC(=O)COC(c1cccc(F)c1F)[C@@H]1CCCN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 5/20 0.46
REN P00797 3/20 0.46
BTK Q06187 1/20 0.40
USP30 Q70CQ3 2/20 0.39
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
GLA P06280 1/20 0.38
HPGD P15428 1/20 0.38
RECQL P46063 1/20 0.38
HSD17B10 Q99714 1/20 0.38
ACKR3 P25106 1/20 0.38
TRPV3 Q8NET8 1/20 0.38
DPP4 P27487 1/20 0.38
PRMT5 O14744 1/20 0.38
WDR77 Q9BQA1 1/20 0.38
GAA P10253 1/20 0.38
KMT2A Q03164 1/20 0.38
KAT7 O95251 1/20 0.38
KAT8 Q9H7Z6 1/20 0.38
ALOX5AP P20292 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8243022 1.00 GPR119 (0.46) GPR119RENBTKUSP30KDM4E
SCHEMBL13502914 1.00 GPR119 (0.46) GPR119RENBTKUSP30KDM4E
SCHEMBL3605918 1.00 GPR119 (0.46) GPR119RENBTKUSP30KDM4E
SCHEMBL1859604 0.92 REN (0.48) GPR119RENUSP30KDM4EALDH1A1
SCHEMBL1859602 0.92 REN (0.48) GPR119RENUSP30KDM4EALDH1A1
SCHEMBL1859608 0.92 REN (0.48) GPR119RENUSP30KDM4EALDH1A1
SCHEMBL3606261 0.92 REN (0.48) GPR119RENUSP30KDM4EALDH1A1
SCHEMBL4974903 0.88 REN (0.46) RENKDM4EALDH1A1HPGDGAA
SCHEMBL3556972 0.87 REN (0.52) GPR119RENBTKUSP30KDM4E
SCHEMBL3556975 0.87 REN (0.52) GPR119RENBTKUSP30KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8487108-B2 Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors VITAE PHARMACEUTICALS, INC. (US) 2013-07-16 US disclosed
EP-1966139-B1 ASPARTIC PROTEASE INHIBITORS VITAE PHARMACEUTICALS INC (US) 2011-12-21 EP disclosed
US-20100048636-A1 Aspartic Protease Inhibitors VITAE PHARMACEUTICALS, INC. 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048636-A1 Aspartic Protease Inhibitors DNPEP, PEPD, SERPINB1 GPR119 3138/4885REN 180/4885BTK 3255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.